JP2006518726A - G四重鎖dna構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用 - Google Patents

G四重鎖dna構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用 Download PDF

Info

Publication number
JP2006518726A
JP2006518726A JP2006502131A JP2006502131A JP2006518726A JP 2006518726 A JP2006518726 A JP 2006518726A JP 2006502131 A JP2006502131 A JP 2006502131A JP 2006502131 A JP2006502131 A JP 2006502131A JP 2006518726 A JP2006518726 A JP 2006518726A
Authority
JP
Japan
Prior art keywords
group
compound
formula
methylquinolinio
amido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006502131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518726A5 (cg-RX-API-DMAC7.html
Inventor
オーギュスタン・イティンジェ
トマス・コールフィールド
パトリック・マイエ
エルヴェ・ブシャール
エリアン・マンダン
ジャン−ルイ・メルニ
リオネール・ギタ
ジャン−フランソワ・リウー
デニス・ゴメス
シャフク・ベルモクタール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute Curie
Original Assignee
Institute Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Curie filed Critical Institute Curie
Publication of JP2006518726A publication Critical patent/JP2006518726A/ja
Publication of JP2006518726A5 publication Critical patent/JP2006518726A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006502131A 2003-02-07 2004-02-05 G四重鎖dna構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用 Pending JP2006518726A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301478A FR2850970B1 (fr) 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
PCT/FR2004/000260 WO2004072027A2 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique

Publications (2)

Publication Number Publication Date
JP2006518726A true JP2006518726A (ja) 2006-08-17
JP2006518726A5 JP2006518726A5 (cg-RX-API-DMAC7.html) 2007-04-05

Family

ID=32731875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006502131A Pending JP2006518726A (ja) 2003-02-07 2004-02-05 G四重鎖dna構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用

Country Status (8)

Country Link
EP (1) EP1603898A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006518726A (cg-RX-API-DMAC7.html)
AU (1) AU2004210753A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407320A (cg-RX-API-DMAC7.html)
CA (1) CA2514105A1 (cg-RX-API-DMAC7.html)
FR (1) FR2850970B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05007648A (cg-RX-API-DMAC7.html)
WO (1) WO2004072027A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101357B2 (en) 2009-04-09 2012-01-24 Panasonic Corporation Method for inhibiting telomerase reaction using an anionic phthalocyanine compound

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
EP2061464A2 (en) * 2006-09-14 2009-05-27 Ramot, at Tel Aviv University Ltd. Combination therapy for tumoral disease treatment
GB0706932D0 (en) * 2007-04-10 2007-05-16 Univ London Pharmacy Ureylene derivatives
WO2009040819A2 (en) 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
JP4410844B1 (ja) 2008-05-27 2010-02-03 パナソニック株式会社 G−quadruplex検出方法、G−quadruplex形成DNA検出方法およびテロメラーゼ活性測定方法
CN108066340B (zh) * 2016-11-10 2020-10-27 中国科学院化学研究所 药物组合物
CN108066341B (zh) * 2016-11-10 2020-10-30 中国科学院化学研究所 化合物在制备抗癌药物中的用途
WO2018211148A1 (en) * 2017-05-19 2018-11-22 Universite De Bretagne Occidentale Bisquinolium derivatives for preventing or treating ebv-related cancers
CN113272294A (zh) * 2018-08-24 2021-08-17 雅典学院生物医学研究基金会 2,6-双(((1h-苯并[d]咪唑-2-基)硫)甲基)吡啶和n2,n6-二苄基吡啶-2,6-二甲酰胺衍生物以及相关化合物作为磷酸肌醇3-激酶(pi3k)抑制剂用于治疗癌症

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040218A1 (fr) * 1999-11-29 2001-06-07 Aventis Pharma S.A. Derives arylamines et leur application comme agent antitelomerase
WO2002055515A1 (fr) * 2001-01-09 2002-07-18 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2002076975A1 (fr) * 2001-03-23 2002-10-03 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2002096903A2 (fr) * 2001-05-28 2002-12-05 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040218A1 (fr) * 1999-11-29 2001-06-07 Aventis Pharma S.A. Derives arylamines et leur application comme agent antitelomerase
WO2002055515A1 (fr) * 2001-01-09 2002-07-18 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2002076975A1 (fr) * 2001-03-23 2002-10-03 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2002096903A2 (fr) * 2001-05-28 2002-12-05 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101357B2 (en) 2009-04-09 2012-01-24 Panasonic Corporation Method for inhibiting telomerase reaction using an anionic phthalocyanine compound

Also Published As

Publication number Publication date
BRPI0407320A (pt) 2006-02-21
FR2850970B1 (fr) 2006-07-07
EP1603898A2 (fr) 2005-12-14
MXPA05007648A (es) 2006-12-15
WO2004072027A3 (fr) 2004-09-23
WO2004072027A2 (fr) 2004-08-26
AU2004210753A1 (en) 2004-08-26
CA2514105A1 (fr) 2004-08-26
FR2850970A1 (fr) 2004-08-13

Similar Documents

Publication Publication Date Title
JP6047556B2 (ja) Lrrk2キナーゼ活性の阻害剤
JP7320263B2 (ja) Ezh2阻害剤及びその使用
US20220227729A1 (en) Identification and use of kras inhibitors
JP7320823B2 (ja) プテリジノン誘導体のegfr阻害剤としての使用
US8124649B2 (en) Oxindole compounds
CN117730075A (zh) 一种吡唑衍生物,其制备方法和在药学上的应用
KR20160076519A (ko) Kras g12c 억제제
RU2763328C2 (ru) Кристаллический ингибитор fgfr4 и его применение
BR112016030697B1 (pt) Compostos inibidores de desmetilase-1 lisina-específica, composição farmacêutica e seus usos
CN107567445B (zh) 可用作哺乳动物酪氨酸激酶ror1活性抑制剂的2-苯基-3h-咪唑并[4,5-b]吡啶衍生物
JP2022526220A (ja) 選択的なcdk12/13阻害剤としての置換された5-シクロプロピル-1h-ピラゾール-3-イル-アミン誘導体
WO2011153942A1 (zh) 氰基喹啉衍生物
KR20170018084A (ko) Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법
JP2004534046A (ja) 化学誘導体および抗テロメラーゼ剤としてのその使用
CA3194868A1 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
ES2972862T3 (es) Compuestos de pirropirimidina como inhibidores de MNK
WO2011127406A2 (en) Acridines as inhibitors of haspin and dyrk kinases
AU2004210753A1 (en) Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent
EP4460492A1 (en) Compounds containing a hydroxyphenyl moiety and their use
US20070232572A1 (en) Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
EP3556756B1 (en) Substituted propanamides as inhibitors of nucleases
EP3632912B1 (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
WO2017192228A1 (en) Pak1 inhibitors and uses thereof
WO2026105155A1 (en) Tricyclic compound for breast and ovarian cancer treatment
CA2721595A1 (en) Polymorphs of hydrochloride salt of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide andmethods of use therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110208